{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:50:15Z","timestamp":1757544615296},"reference-count":10,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":6510,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1990,9]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>To study the activation of T lymphocytes in hyperthyroid Graves'disease, the serum concentrations of soluble interleukin 2 receptors (sIL2R) were determined during active thyrotoxicosis and following the return to a euthyroid state with carbimazole therapy. Serum sIL2R was measured by an enzyme linked immunoassay. The mean |Mp SD serum sIL2R concentration during untreated hyperthyroidism was elevated as compared with controls (919.1 |Mp 523.4 <jats:italic>vs<\/jats:italic> 374.2|Mp 189\u20104 U\/ml, P&lt;0.005). However, after carbimazole therapy the serum sIL2R in euthyroid patients fell to 377\u20139 |Mp 90.3 U\/ml, which did not differ from healthy controls. Serum sIL2R correlated significantly with the serum free T3 only during hyperthyroidism (<jats:italic>r<\/jats:italic>= 0.678, P &lt; 0.01). Our study suggests that in\u2010vivo measurement of serum sIL2R released from activated T lymphocytes is a useful immunological indicator of disease activity.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1990.tb00496.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T11:10:36Z","timestamp":1205752236000},"page":"317-321","source":"Crossref","is-referenced-by-count":15,"title":["SERUM SOLUBLE INTERLEUKIN 2 RECEPTOR IN HYPERTHYROID Graves'DISEASE AND EFFECT OF CARBIMAZOLE THERAPY"],"prefix":"10.1111","volume":"33","author":[{"given":"C. C.","family":"CHOW","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. N.","family":"LAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C. K.","family":"LEUNG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C. N.","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. S.","family":"COCKRAM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-6-2-183"},{"key":"e_1_2_1_3_1","first-page":"602","article-title":"T lymphocyte activation in euthyroid Graves' ophthalmopathy: soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production","volume":"120","author":"Lai K. N.","year":"1989","journal-title":"Acta Endocrinologica (Copenh.)"},{"key":"e_1_2_1_4_1","unstructured":"Nakanishi K. Taniguchi Y. Onji M. Yamaguchi S. Tamai M. Ichiba T. Tanaka A.andOhta Y.(1988)Increased levels of soluble interleukin 2 receptors in Graves' disease. 8th International Congress of Endocrinology Kyoto Japan Abstract 12\u201018\u2010011."},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00918743"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00917899"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.160.4.1126"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.4049\/jimmunol.135.5.3172","article-title":"Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro","volume":"135","author":"Rubin L. A.","year":"1985","journal-title":"Journal of Immunology"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00916949"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1986.tb01712.x"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-5-2-309"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1990.tb00496.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1990.tb00496.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:29:44Z","timestamp":1698020984000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1990.tb00496.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1990,9]]}},"alternative-id":["10.1111\/j.1365-2265.1990.tb00496.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1990.tb00496.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,9]]}}}